Miami, Florida, USA
Robust regulatory oversight and stringent quality control are fundamental to assuring the integrity and safety of cell and gene therapy (CGT) manufacturing. As the sector expands internationally, harmonisation and compliance with different regulatory approaches have been prioritised. Creating clear and consistent frameworks enhances product safety and advances global access to innovative therapies.